These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19606452)

  • 1. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.
    Yoshimura R; Umene-Nakano W; Suzuki A; Ueda N; Miyamoto K; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    Hum Psychopharmacol; 2009 Aug; 24(6):489-94. PubMed ID: 19606452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
    Tomita T; Yasui-Furukori N; Nakagami T; Tsuchimine S; Ishioka M; Kaneda A; Sugawara N; Kaneko S
    PLoS One; 2014; 9(5):e98099. PubMed ID: 24858363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.
    Lotrich FE; Pollock BG; Kirshner M; Ferrell RF; Reynolds Iii CF
    J Psychiatry Neurosci; 2008 Mar; 33(2):123-30. PubMed ID: 18330458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
    Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH
    Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder.
    Yoshimura R; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Atake K; Nakamura J
    Hum Psychopharmacol; 2013 Sep; 28(5):466-70. PubMed ID: 23813968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine.
    Lee SH; Choi TK; Lee E; Seok JH; Lee SH; Lee HS; Kim SJ
    Neuropsychobiology; 2010 Aug; 62(3):198-206. PubMed ID: 20664233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder.
    Ishiguro S; Watanabe T; Ueda M; Saeki Y; Hayashi Y; Akiyama K; Saito A; Kato K; Inoue Y; Shimoda K
    Eur J Clin Pharmacol; 2011 Dec; 67(12):1213-21. PubMed ID: 21688171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder.
    Bozina N; Peles AM; Sagud M; Bilusic H; Jakovljevic M
    World J Biol Psychiatry; 2008; 9(3):190-7. PubMed ID: 17853254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism.
    Umene-Nakano W; Yoshimura R; Ueda N; Suzuki A; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    J Psychopharmacol; 2010 Dec; 24(12):1764-71. PubMed ID: 19825907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.
    Pollock BG; Ferrell RE; Mulsant BH; Mazumdar S; Miller M; Sweet RA; Davis S; Kirshner MA; Houck PR; Stack JA; Reynolds CF; Kupfer DJ
    Neuropsychopharmacology; 2000 Nov; 23(5):587-90. PubMed ID: 11027924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.
    Won ES; Chang HS; Lee HY; Ham BJ; Lee MS
    Neuropsychobiology; 2012; 66(4):221-9. PubMed ID: 23095326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.
    Manoharan A; Shewade DG; Rajkumar RP; Adithan S
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1215-1220. PubMed ID: 27439447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population.
    Wang XC; Xu DJ; Chen GH; Xia Q; Liu LN
    Ther Drug Monit; 2014 Oct; 36(5):612-7. PubMed ID: 24577123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
    Kato M; Wakeno M; Okugawa G; Fukuda T; Takekita Y; Hosoi Y; Azuma J; Kinoshita T; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1041-4. PubMed ID: 18325652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin transporter polymorphism and bleeding time during SSRI therapy.
    Hougardy DM; Egberts TC; van der Graaf F; Brenninkmeijer VJ; Derijks LJ
    Br J Clin Pharmacol; 2008 May; 65(5):761-6. PubMed ID: 18279474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism in the serotonin transporter gene-linked polymorphic region and response to serotonin reuptake inhibitors in patients with premature ejaculation.
    Ozbek E; Otunctemur A; Simsek A; Polat EC; Ozcan L; Köse O; Cekmen M
    Clinics (Sao Paulo); 2014 Nov; 69(11):710-3. PubMed ID: 25518026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
    Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
    J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
    Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB
    J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.